Form 4: Xencor Inc. Executive John R. Desjarlais Reports Stock and Option Awards

John R. Desjarlais, Senior Vice President & CSO of Xencor Inc., reports the acquisition of restricted stock units and stock options.

Summary

• John R. Desjarlais, a Senior Vice President & CSO at Xencor Inc., filed a Form 4 on March 5, 2025, reporting transactions related to the company's stock.
• On March 4, 2025, Desjarlais acquired 29,851 shares of common stock through restricted stock units (RSUs).
• These RSUs vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent upon continuous service.
• Desjarlais also acquired options to purchase 89,552 shares of common stock at an exercise price of $14.15.
• These options vest 25% on the one-year anniversary of March 4, 2025, and then 1/48th monthly thereafter, fully vesting on the four-year anniversary, also contingent upon continuous service.
• Following these transactions, Desjarlais beneficially owns 246,271 shares of common stock and options for 89,552 shares.
• A power of attorney was executed on February 19, 2025, granting Bassil I. Dahiyat, Bart Jan Cornelissen, and Celia E. Eckert the authority to act on Desjarlais's behalf for SEC filings.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting required information about stock and option grants. It's a standard practice and doesn't inherently indicate positive or negative sentiment, but the grants themselves can be seen as a positive sign of incentivizing key personnel.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedules encourage long-term commitment and performance from the executive.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedules of the stock options and RSUs suggest an expectation of continued service and contribution from the executive.

Industry Context

This type of filing is standard for publicly traded companies and reflects compensation practices for executives. Stock options and RSUs are common tools used to incentivize and retain key personnel in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, similar to companies like Amgen, Regeneron, and Gilead.
• Vesting schedules of 3-4 years are also standard practice to ensure long-term alignment with company goals.
• The size of the grant would need to be compared to similar roles and company size to determine if it is in line with industry benchmarks.

Stakeholder Impact

• Shareholders may view the stock and option grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may be motivated by the knowledge that executives are incentivized to improve company performance.

Key Dates